Please enable JS

AB-Cube

Founded in 2006, AB-Cube revolutionised the life sciences and international healthcare industry with a cloud-based vigilance solution for management of adverse events. They offer a wide range of dedicated solutions like pharmacovigilance, medical device safety, nutrivigilance and CosmEthics® for cosmetovigilance.

 

They have a diverse international client base, consisting of organisations, academia, CROs and pharmaceutical companies, who are proud to collaborate with AB-Cube  for their pharmacovigilance needs.

 

Learn more: www.ab-cube.com

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

Meet Us at DIA Europe 2025 – Booth I2

February 27, 2025

18 – 20 march – Basel, Switzerland Register Now DIA Europe 2025 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2025 will be the prime opportunity to discuss how collaboration and […]

READ MORE
telemedecine technologies news

Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time

February 27, 2025

Med City News From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out. Somewhere in a laboratory, tucked away in its vessel, […]

READ MORE
telemedecine technologies news

Three Ways AI is Revolutionizing Clinical Development

February 27, 2025

Applied Clinical Trials Artificial intelligence (AI) is the biggest transformation in life sciences in the last 25 years—an advancement akin to mapping the human genome, with potential for a much higher rate of scientific breakthroughs over the next decade. But there’s still a lot to consider when applying AI to clinical development and product commercialization, […]

READ MORE